Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Health Network, Toronto
Goals of this study include:
* Explore which circulating endocrine markers or endocrine related markers have the best potential to predict clinical response to abiraterone acetate in CRPC patients
* Explore the utility of microRNA, circulating DNA and exosome analyses in complementing the previous objective
Age
Any age
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Signed written informed consent. Before any study procedures are performed, subjects (or their legally acceptable representatives) will have the details of the study described to them, and they will be given a written informed consent document to read. If subjects consent to participate in the study, they will indicate that consent by signing and dating the informed consent document in the presence of study personnel
Be suitable for receiving treatment with abiraterone acetate and prednisone
Patients must have histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology
Patients may not receive any other investigational agent or dose escalation of abiraterone acetate during study participation
Patient consents to comply to treatment with abiraterone acetate as directed by their physician
You may not be if
Taking a dose of abiraterone acetate other than 1g daily or lack of compliance to daily dosing of abiraterone acetate and prednisone
Patients receiving spironolactone or any other steroidogenic compounds in excess of the associated prednisone 5mg bid are excluded due to the potential for androgen receptor agonism
Clareo Health | A Correlative Study of Biomarkers of Resistance in Patients With Castrate Resistant Prostate Cancer Treated With Abiraterone
